



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOVEMBER 14, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594054

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061737/0170
NUMBER OF PAGES: 12

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
GERLACH, AARON

DOC DATE: 09/22/2022

ASSIGNOR:
CHAPMAN, MARK

DOC DATE: 09/22/2022

ASSIGNOR:
MOWREY, DAVID

DOC DATE: 09/23/2022

ASSIGNOR:
NAIR, ANIL

DOC DATE: 09/24/2022

ASSIGNOR:
LEBRETON, SYLVAIN

DOC DATE: 09/23/2022

ASSIGNOR:
SMRCINA, MARTIN

DOC DATE: 09/23/2022

ASSIGNOR:
NAGARAJAN, KARTHIGEYAN

DOC DATE: 09/23/2022

ASSIGNOR:
MECHIN, INGRID

DOC DATE: 09/23/2022

ASSIGNEE:
ICAGEN, LLC
1035 SWABIA COURT, SUITE 110,
NEWCASTLE NORTH
DURHAM, NORTH CAROLINA 27703

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 1 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Declaration

This Declaration is directed to U.S. or International Application No. **63/281,133** filed November 19, 2021 and incorporating any amendments made thereto prior to the signature date of this Declaration.

As a named inventor, I declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

Assignment from Inventors

WHEREAS, **above-identified inventors** (individual(s) hereinafter "ASSIGNOR") invented certain new and useful improvements, technology, inventions, developments, ideas, ornamental designs, or discoveries related to NOVEL PYRIDINE COMPOUNDS (collectively hereinafter referred to as the "Work") for which an application for Letters Patent in the United States (identified above) has been filed or prepared for filing with the United States Patent and Trademark Office (hereinafter the "Application"), and ASSIGNOR desires to assign or confirm assignment of the Work and the Application to the below identified Assignee.

AND WHEREAS, **Icagen, LLC**, with its principal place of business at **1035 Swabia Court, Suite 110, Newcastle North, Durham, NC 27703** (hereinafter the "ASSIGNEE"), desires to acquire or confirm ownership of the entire right, title, and interest in and to the Application and the Work.

NOW, THEREFORE, for good and valuable consideration of which receipt is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred, and set over, and by these presents does hereby sell, assign, transfer, and set over, unto said ASSIGNEE, **its** successors, legal representatives, and assigns, the entire right, title, and interest throughout the world in and to the Application and the Work, including: all provisional applications relating to the Work and the Application; all nonprovisional applications claiming priority to aforementioned provisional(s) and/or the Application, including, all divisions, continuations, continuations-in-part, and reissues, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof; and all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals, and reissues thereof.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, **its** successors, legal representatives, and assigns.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))*Application Data Sheet filed previously or concurrently***Docket No.:** P37221

Page 2 of 12

Title: NOVEL PYRIDINE COMPOUNDS**Inventors:** Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, **its** successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will: communicate to said ASSIGNEE, **its** successors, legal representatives, and assigns any facts known to ASSIGNOR respecting the Work; testify in any legal proceeding; assist in the preparation of any other Patent Property relating to the Application and the Work or any improvements made thereto; sign/execute all lawful papers; authorize the filing of, execute, and make all rightful oaths and/or declarations in connection with the Application and the Work including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications; and generally do everything possible to aid the ASSIGNEE, **its** successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Work in all countries.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 3 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Aaron Gerlach

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 22nd day of September,
2022

Signature: _____

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 4 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Mark Chapman

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 22nd day of September,
2022.

Signature: _____



Signature before a Notary is desirable but not required. When signed in
presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 7 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: David Mowrey

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 23rd day of September,
2022.

Signature: David Mowrey

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 8 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Anil Nair

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 24th day of September,
2022.

Signature:

 Anil C. Nair

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 9 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Sylvain Lebreton

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 23 day of September,
2022.

Signature: _____



Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 10 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Martin Smrcina

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this ____ day of 09/23/2022,
20____.

Signature: _____



Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 11 of 12

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Karthigeyan Nagarajan

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 23 day of September,
2022.

Signature: 

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 12 of 12


Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Aaron Gerlach, Mark Chapman, Ashley Banks, Matthew D. Fuller, David Mowrey, Anil Nair
Sylvain Lebreton, Martin Smrcina, Karthigeyan Nagarajan, Ingrid Mechin

Legal Name of Inventor: Ingrid Mechin

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 23rd day of September, 2022.

Signature: _____



Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOVEMBER 14, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594577

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061741/0873
NUMBER OF PAGES: 7

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
DAVIDSON, JAMES

DOC DATE: 09/28/2022

ASSIGNOR:
GRAHAM, CHRISTOPHER JOHN

DOC DATE: 09/28/2022

ASSIGNOR:
DAVIES, NICHOLAS GARETH MORSE

DOC DATE: 09/26/2022

ASSIGNEE:
VERNALIS (R&D) LIMITED
GRANTA PARK, GREAT ABINGTON
CAMBRIDGE, UNITED KINGDOM CB21 6GB

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 1 of 6

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: James Davidson, Christopher John Graham, Luke James Thompson,
Nicholas Gareth Morse Davies

Declaration

This Declaration is directed to U.S. or International Application No. **63/281,133** filed November 19, 2021 and incorporating any amendments made thereto prior to the signature date of this Declaration.

As a named inventor, I declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

Assignment from Inventors

WHEREAS, **above-identified inventors** (individual(s) hereinafter "ASSIGNOR") invented certain new and useful improvements, technology, inventions, developments, ideas, ornamental designs, or discoveries related to NOVEL PYRIDINE COMPOUNDS (collectively hereinafter referred to as the "Work") for which an application for Letters Patent in the United States (identified above) has been filed or prepared for filing with the United States Patent and Trademark Office (hereinafter the "Application"), and ASSIGNOR desires to assign or confirm assignment of the Work and the Application to the below identified Assignee.

AND WHEREAS, **Vernalis (R&D) Limited**, with its principal place of business at **Granta Park, Great Abington, Cambridge, CB21 6GB, United Kingdom** (hereinafter the "ASSIGNEE"), desires to acquire or confirm ownership of the entire right, title, and interest in and to the Application and the Work.

NOW, THEREFORE, for good and valuable consideration of which receipt is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred, and set over, and by these presents does hereby sell, assign, transfer, and set over, unto said ASSIGNEE, **its** successors, legal representatives, and assigns, the entire right, title, and interest throughout the world in and to the Application and the Work, including: all provisional applications relating to the Work and the Application; all nonprovisional applications claiming priority to aforementioned provisional(s) and/or the Application, including, all divisions, continuations, continuations-in-part, and reissues, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof; and all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals, and reissues thereof.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, **its** successors, legal representatives, and assigns.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))*Application Data Sheet filed previously or concurrently***Docket No.:** P37221

Page 2 of 6

Title: NOVEL PYRIDINE COMPOUNDS**Inventors:** James Davidson, Christopher John Graham, Luke James Thompson,
Nicholas Gareth Morse Davies

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, **its** successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will: communicate to said ASSIGNEE, **its** successors, legal representatives, and assigns any facts known to ASSIGNOR respecting the Work; testify in any legal proceeding; assist in the preparation of any other Patent Property relating to the Application and the Work or any improvements made thereto; sign/execute all lawful papers; authorize the filing of, execute, and make all rightful oaths and/or declarations in connection with the Application and the Work including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications; and generally do everything possible to aid the ASSIGNEE, **its** successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Work in all countries.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 3 of 6

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: James Davidson, Christopher John Graham, Luke James Thompson,
Nicholas Gareth Morse Davies

Legal Name of Inventor: James Davidson

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 28th day of SEPTEMBER,
2022.

Signature: _____



Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 4 of 6

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: James Davidson, Christopher John Graham, Luke James Thompson,
Nicholas Gareth Morse Davies

Legal Name of Inventor: Christopher John Graham

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 28th day of SEPTEMBER,
2022.

Signature: 

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 6 of 6

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: James Davidson, Christopher John Graham, Luke James Thompson,
Nicholas Gareth Morse Davies

Legal Name of Inventor: Nicholas Gareth Morse Davies

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 26th day of SEPTEMBER,
2022.

Signature: Nicholas Davies

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOVEMBER 14, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594447

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061740/0940
NUMBER OF PAGES: 7

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
MA, NINA

DOC DATE: 09/29/2022

ASSIGNOR:
LI, RONGHUA

DOC DATE: 09/26/2022

ASSIGNOR:
SAFAROVA, ALENA

DOC DATE: 09/26/2022

ASSIGNEE:
ICAGEN, INC.
2090 E. INNOVATION PARK DRIVE
ORO VALLEY, ARIZONA 85755

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 1 of 5

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Nina Ma, Ronghua Li, Alena Safarova

Declaration

This Declaration is directed to U.S. or International Application No. **63/281,133** filed November 19, 2021 and incorporating any amendments made thereto prior to the signature date of this Declaration.

As a named inventor, I declare that:

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

Nunc Pro Tunc Assignment

WHEREAS, **above-identified inventors** (individual(s) hereinafter "ASSIGNOR") invented certain new and useful improvements, technology, inventions, developments, ideas, ornamental designs, or discoveries related to NOVEL PYRIDINE COMPOUNDS (collectively hereinafter referred to as the "Work") for which an application for Letters Patent in the United States (identified above) has been filed or prepared for filing with the United States Patent and Trademark Office (hereinafter the "Application"), and ASSIGNOR desires to assign or confirm assignment of the Work and the Application to the below identified Assignee;

AND WHEREAS, **lcagen, Inc.**, with its principal place of business at **2090 E. Innovation Park Drive,**

Oro Valley AZ 85755 (hereinafter the "ASSIGNEE"), desires to confirm ownership of the entire right, title, and interest in and to the Application and the Work as of February 10, 2020.

AND WHEREAS, ASSIGNOR invented the Work prior to February 10, 2020, and prior to that date assigned and agreed to assign the Work to ASSIGNEE.

NOW, THEREFORE, for good and valuable consideration of which receipt is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred, and set over, and by these presents does hereby sell, assign, transfer, and set over, unto said ASSIGNEE, **its** successors, legal representatives, and assigns, *nunc pro tunc* effective as of February 10, 2020, the entire right, title, and interest throughout the world in and to the Application and the Work, including: all provisional applications relating to the Work and the Application; all nonprovisional applications claiming priority to aforementioned provisional(s) and/or the Application, including, all divisions, continuations, continuations-in-part, and reissues, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof; and all rights of priority under International Conventions and any related Letters Patent which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals, and reissues thereof, including the right to sue for past infringement.

ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, **its** successors, legal representatives, and assigns.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))*Application Data Sheet filed previously or concurrently***Docket No.:** P37221

Page 2 of 5

Title: NOVEL PYRIDINE COMPOUNDS**Inventors:** Nina Ma, Ronghua Li, Alena Safarova

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, **its** successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will: communicate to said ASSIGNEE, **its** successors, legal representatives, and assigns any facts known to ASSIGNOR respecting the Work; testify in any legal proceeding; assist in the preparation of any other Patent Property relating to the Application and the Work or any improvements made thereto; sign/execute all lawful papers; authorize the filing of, execute, and make all rightful oaths and/or declarations in connection with the Application and the Work including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications; and generally do everything possible to aid the ASSIGNEE, **its** successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Work in all countries.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 3 of 5

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Nina Ma, Ronghua Li, Alena Safarova

Legal Name of Inventor: Nina Ma

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 29th day of SEPTEMBER
2022.

Signature: 

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221


Page 4 of 5

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Nina Ma, Ronghua Li, Alena Safarova

Legal Name of Inventor: Ronghua Li

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 26th day of September
20 22

Signature: 

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

COMBINED DECLARATION & ASSIGNMENT (37 CFR 1.63(e))

Application Data Sheet filed previously or concurrently

Docket No.: P37221

Page 5 of 5

Title: NOVEL PYRIDINE COMPOUNDS

Inventors: Nina Ma, Ronghua Li, Alena Safarova

Legal Name of Inventor: Alena Safarova

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this 26 day of September, 2022.

Signature: _____

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOVEMBER 14, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594614

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061742/0055
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
VERNALIS (R&D) LIMITED

DOC DATE: 10/04/2022

ASSIGNEE:
ICAGEN, LLC
5980 HORTON STREET, SUITE 600
EMERYVILLE, CALIFORNIA 94608

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

APPLICATION NUMBER: 63281140
PATENT NUMBER:
TITLE: PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

ASSIGNMENT

WHEREAS, **Vernalis (R&D) Limited**, a company incorporated in England and Wales, having an address at Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom (hereinafter "ASSIGNOR") represents and warrants that it has provided services to the ASSIGNEE (as defined below) which has led to certain new and useful improvements for patent applications and/or issued patents listed within or attached to this document (hereinafter "the Applications");

<u>Application No.</u>	<u>Filing Date</u>	<u>Title</u>
63/281,133	November 19, 2021	NOVEL PYRIDINE COMPOUNDS
63/281,140	November 19, 2021	NOVEL PYRIDINE COMPOUNDS
63/292,482	December 22, 2021	NOVEL CYCLOPROPYL COMPOUNDS
63/310,219	February 15, 2022	NEW BICYCLOPENTANE DERIVATIVES

AND WHEREAS, **icagen, LLC**, a Delaware limited liability company having an address at 5980 Horton Street, Suite 600, Emeryville, CA 94608 (hereinafter "ASSIGNEE") desires to acquire or confirm ownership of ASSIGNEE's right, title, and interest in and to the Applications.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred, and set over, and by these presents does hereby sell, assign, transfer, and set over, unto said ASSIGNEE, its successors, legal representatives, and assigns, its entire right, title, and interest throughout the world in and to the Applications, including: all provisional applications relating to any of the Applications; all nonprovisional applications claiming priority to aforementioned provisional(s) and/or any of the Applications, including, all divisions, continuations, continuations-in-part, and reissues thereof, and all Letters Patent of the United States which may be granted thereon, and all reissues, and extensions thereof; all rights of priority under International Conventions and any related Letters Patent and applications for Letters Patents which may hereafter be granted or filed in any country or countries foreign to the United States, all extensions, renewals, and reissues thereof; and ASSIGNOR hereby authorizes and requests the Commissioner for Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all related Letters Patent to the ASSIGNEE, its successors, legal representatives, and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR DOES HEREBY acknowledge and agree that the assigned scope of the Applications includes any currently recited claims, all embodiments, and all claims supported by the Applications; ASSIGNOR agrees not to contest or disparage claim scope thus supported (including in any later-filed continuing patent applications) for any claims deemed patentable by any government patent office. ASSIGNOR also agrees not to challenge the validity, including as a defense to patent infringement, of any issued patent claims resulting from or based on the Applications, regardless of the scope of any such claims.

AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of said Letters Patent before or after issuance.

AND ASSIGNOR DOES HEREBY covenant and agree that ASSIGNOR will at ASSIGNEE'S cost: communicate to said ASSIGNEE, its successors, legal representatives, and assigns any facts known to ASSIGNOR respecting the Applications; testify in any legal proceeding; assist in the preparation of any other provisional or non-provisional applications relating to the Applications or any improvements made thereto; sign/execute all lawful papers; authorize the filing of, execute, and make all rightful oaths and/or declarations in connection with the Applications including any improvements made thereto, any patent applications filed therefrom, and any continuing application filed from any of the aforementioned applications; and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives, and assigns, to obtain and enforce proper patent protection for the Applications in all countries.

AND ASSIGNOR DOES HEREBY agree that if any term or provision of this agreement becomes invalid or unenforceable, the remainder shall survive unaffected.

IN TESTIMONY WHEREOF, I hereunto set my hand this 4th day of October, 2022.

Vernalis (R&D) Limited (Conveying Party)


Icagen, LLC (Receiving Party)

By: 

Name: Mike Wood

Title: Managing Director

Date: 4th October 2022

By: 

Name: Douglas Krafte

Title: Site Head and General Manager

Date: 11 OCTOBER 2022

Signature before a Notary is desirable but not required. When signed in presence of a Notary, please attach the appropriate notarial documentation.

ASSIGN-ENTITY

56298847



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOVEMBER 14, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594664

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061742/0296
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
NORCROSS, ROGER DAVID

DOC DATE: 10/18/2022

ASSIGNOR:
REDONDO, ROGER

DOC DATE: 10/18/2022

ASSIGNEE:
F. HOFFMANN-LA ROCHE AG
GRENZACHERSTRASSE 124
BASEL, SWITZERLAND 4070

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

Case No. P37221-US

CONFIRMATORY ASSIGNMENT

I/We, the undersigned

Inventor(s)

Roger David NORCROSS, a British citizen
c/o F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Switzerland

Roger REDONDO, a Spanish citizen
c/o F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Switzerland

Employed by:

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

Inventor(s)

Mark CHAPMAN
Aaron GERLACH
Sylvain LEBRETON
Ronghua LI
Nina MA
Ingrid MECHIN
David MOWREY
Karthigeyan NAGARAJAN
Anil NAIR
Alena SAFAROVA
Martin SMRCINA

Nicholas Gareth Morse DAVIES
James DAVIDSON
Christopher John GRAHAM

Employed by:

Icagen, LLC
Icagen, LLC
Icagen, LLC
Icagen, Inc.
Icagen, Inc.
Icagen, LLC
Icagen, LLC
Icagen, LLC
Icagen, LLC
Icagen, Inc.
Icagen, LLC

Vernalis (R&D) Limited
Vernalis (R&D) Limited
Vernalis (R&D) Limited

hereinafter CO-INVENTOR(S)

of the invention entitled:

NOVEL PYRIDINE COMPOUNDS

for which (a) priority application(s) was (were) filed with the

US Patent Office
as outlined below:

Case No.
P37221-US

Country
US

Filing Date
19. November 2021

Serial No.
63/281133

ASSIGNOR(S) acknowledge(s) the previous transfer to

Case No. P37221-US

F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Switzerland

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the inventions disclosed in the priority application(s) set forth above by operation of law, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the inventions disclosed in the patent application(s) set forth above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest in, to, and deriving from the invention and to the above priority application(s), including the right to claim priority.

The assignment of the rights of the CO-INVENTOR(S) is subject to a separate assignment agreement. ASSIGNOR(S) explicitly approve(s) that assignment.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name and at its own costs that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

ASSIGNEE and ASSIGNOR hereby acknowledge, confirm, and agree that ASSIGNOR has been fully and adequately compensated for all rights granted or assigned to ASSIGNEE hereunder.

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR(S)

18. 10. 2022
Basel, Date

Roger David Norcross
Roger David NORCROSS

18 10 2022
Basel, Date

Roger Redondo
Roger REDONDO

ASSIGNEE

F. Hoffmann-La Roche AG

Basel, October 18, 2022
Basel, Date

Antonio Natoli
Holder of procuration

Ina Gengelbach
Mandatory



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MARCH 6, 2024

PTAS

MR. XIANGJING ZHAN
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

508397772

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 02/21/2024

REEL/FRAME: 066642/0166
NUMBER OF PAGES: 5

BRIEF: CORRECTIVE ASSIGNMENT TO CORRECT THE THE SECOND INVENTOR'S NAME PREVIOUSLY RECORDED AT REEL: 61742 FRAME: 296. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT.

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
NORCROSS, ROGER DAVID

DOC DATE: 10/18/2022

ASSIGNOR:
REDONDO PENA, ROGER LLUIS

DOC DATE: 10/18/2022

ASSIGNEE:
F. HOFFMANN-LA ROCHE AG
GRENZACHERSTRASSE 124
BASEL, SWITZERLAND 4070

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Assignment ID: 40852

Electronic Version v1.1
Stylesheet Version v1.2

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT										
NATURE OF CONVEYANCE:	Corrective Assignment to correct the second inventor's name previously recorded on Reel 61742 Frame 296. Assignor(s) hereby confirms the the assignment..										
CONVEYING PARTY DATA											
<table border="1"><tr><th>Name</th><th>Execution Date</th></tr><tr><td>Roger David Norcross</td><td>10/18/2022</td></tr><tr><td>Roger Lluís Redondo Pena</td><td>10/18/2022</td></tr></table>	Name	Execution Date	Roger David Norcross	10/18/2022	Roger Lluís Redondo Pena	10/18/2022					
Name	Execution Date										
Roger David Norcross	10/18/2022										
Roger Lluís Redondo Pena	10/18/2022										
RECEIVING PARTY DATA											
<table border="1"><tr><td>Name:</td><td>F. Hoffmann-La Roche AG</td></tr><tr><td>Street Address:</td><td>Grenzacherstrasse 124</td></tr><tr><td>City:</td><td>Basel</td></tr><tr><td>State/Country:</td><td>SWITZERLAND</td></tr><tr><td>Postal Code:</td><td>4070</td></tr></table>	Name:	F. Hoffmann-La Roche AG	Street Address:	Grenzacherstrasse 124	City:	Basel	State/Country:	SWITZERLAND	Postal Code:	4070	
Name:	F. Hoffmann-La Roche AG										
Street Address:	Grenzacherstrasse 124										
City:	Basel										
State/Country:	SWITZERLAND										
Postal Code:	4070										
PROPERTY NUMBERS Total:1											
<table border="1"><tr><th>Property Type</th><th>Number</th></tr><tr><td>Application Number:</td><td>63281133</td></tr></table>	Property Type	Number	Application Number:	63281133							
Property Type	Number										
Application Number:	63281133										
CORRESPONDENCE DATA											
Fax Number: 9735960545											
Phone: (973)596-4500											
Email: IPDocket@gibbonslaw.com,xzhan@gibbonslaw.com											
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>											
Correspondent Name: Mr. Xiangjing Zhan											
Address Line 1: One Gateway Center											
Address Line 2: Gibbons P.C.											
Address Line 4: Newark , NEW JERSEY 07102											
ATTORNEY DOCKET NUMBER:	036844-106335 (P37221)										
NAME OF SUBMITTER:	Xiangjing Zhan										

Signature:	Xiangjing Zhan
Date:	02/21/2024
TOTAL ATTACHMENTS: 1 source= 37221_correctedassignment.pdf	

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7641554

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ROGER DAVID NORCROSS	10/18/2022
ROGER REDONDO	10/18/2022
RECEIVING PARTY DATA	
Name:	F. HOFFMANN-LA ROCHE AG
Street Address:	GRENZACHERSTRASSE 124
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4070
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	63281133
CORRESPONDENCE DATA	
Fax Number:	(973)596-0545
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	973-596-4500
Email:	IPDocket@gibbonslaw.com
Correspondent Name:	IP DOCKET ADMINISTRATOR
Address Line 1:	ONE GATEWAY CENTER
Address Line 2:	GIBBONS P.C.
Address Line 4:	NEWARK, NEW JERSEY 07102
ATTORNEY DOCKET NUMBER:	036844-106335 (P37221)
NAME OF SUBMITTER:	XIANGJING ZHAN
SIGNATURE:	/Xiangjing Zhan/
DATE SIGNED:	11/11/2022
Total Attachments: 2	
source=37221_assignment FHLR inventors signed#page1.tif	
source=37221_assignment FHLR inventors signed#page2.tif	

Case No. P37221-US

CONFIRMATYOY ASSIGNMENT

I/We, the undersigned

Inventor(s)

Roger David NORCROSS, a British citizen
c/o F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Switzerland

~~ROGER REDONDO~~ *ROGER LLUIS REDONDO PENA*

~~Roger REDONDO~~, a Spanish citizen *RRP*
c/o F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Switzerland *1/19/2024*

Employed by:

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG

hereinafter ASSIGNOR(S), herewith declare that I am/we are joint inventor(s) together with

Inventor(s)

Mark CHAPMAN
Aaron GERLACH
Sylvain LEBRETON
Ronghua LI
Nina MA
Ingrid MECHIN
David MOWREY
Karthigeyan NAGARAJAN
Anil NAIR
Alena SAFAROVA
Martin SMRCINA

Nicholas Gareth Morse DAVIES
James DAVIDSON
Christopher John GRAHAM

Employed by:

Icagen, LLC
Icagen, LLC
Icagen, LLC
Icagen, Inc.
Icagen, Inc.
Icagen, LLC
Icagen, LLC
Icagen, LLC
Icagen, LLC
Icagen, Inc.
Icagen, LLC

Vernalis (R&D) Limited
Vernalis (R&D) Limited
Vernalis (R&D) Limited

hereinafter CO-INVENTOR(S)

of the invention entitled:

NOVEL PYRIDINE COMPOUNDS

for which (a) priority application(s) was (were) filed with the

US Patent Office
as outlined below:

Case No.
P37221-US

Country
US

Filing Date
19. November 2021

Serial No.
63/281133

ASSIGNOR(S) acknowledge(s) the previous transfer to

Case No. P37221-US

F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Switzerland

hereinafter ASSIGNEE, of all right, title, and interest in, to, and deriving from the inventions disclosed in the priority application(s) set forth above by operation of law, contract, or otherwise.

As far as right, title, and interest of the ASSIGNOR(S) in, to, and deriving from the inventions disclosed in the patent application(s) set forth above may not have been transferred to ASSIGNEE, ASSIGNOR(S) herewith assign(s) to ASSIGNEE all right, title, and interest in, to, and deriving from the invention and to the above priority application(s), including the right to claim priority.

The assignment of the rights of the CO-INVENTOR(S) is subject to a separate assignment agreement. ASSIGNOR(S) explicitly approve(s) that assignment.

ASSIGNEE by virtue of this assignment thereof shall have the exclusive right and is fully entitled to claim priority of the priority application(s) set forth above, to apply for, obtain, and own patents worldwide in its own name and at its own costs that claim priority to and are based in whole or in part on the priority application(s), to maintain any patent granted thereupon and to discontinue any patents or patent applications as it deems appropriate.

ASSIGNEE and ASSIGNOR hereby acknowledge, confirm, and agree that ASSIGNOR has been fully and adequately compensated for all rights granted or assigned to ASSIGNEE hereunder.

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR(S)

18. 10. 2022
Basel, Date

Roger David Norcross
Roger David NORCROSS

18 10 2022
Basel, Date

~~Roger REDONDO~~
ROGER LLUIS REDONDO PERA RRT
1/19/2024

ASSIGNEE

F. Hoffmann-La Roche AG

Basel, October 18, 2022
Basel, Date

Antonio Natoli
Holder of procuration

Ina Gengelbach
Mandatory



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

DECEMBER 2, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594706

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061931/0735
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:

F. HOFFMANN-LA ROCHE AG

DOC DATE: 10/27/2022

ASSIGNEE:

HOFFMANN-LA ROCHE INC.
150 CLOVE ROAD, OVERLOOK AT GREAT
NOTCH
SUITE 8
LITTLE FALLS, NEW JERSEY 07424

APPLICATION NUMBER: 63281133

FILING DATE: 11/19/2021

PATENT NUMBER:

ISSUE DATE:

TITLE: NOVEL PYRIDINE COMPOUNDS

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

CONFIRMATORY ASSIGNMENT

F. Hoffmann-La Roche AG ("ASSIGNOR") a corporation duly organized under the laws of Switzerland and having its principal place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland

acknowledges the previous transfer to

Hoffmann-La Roche Inc. ("ASSIGNEE") a corporation of the State of New Jersey, United States of America, having its principal place of business at 150 Clove Road, Overlook at Great Notch, Suite 8, Little Falls, New Jersey 07424, United States of America

for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, of all right, title, and interest in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below for the territory of the United States of America and its possessions by operation of law, contract, or otherwise, and any Letters Patent which may hereafter be granted on the same in the United States including any application claiming priority under 35 U.S.C. §119(e), divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof.

As far as the right, title, and interest of ASSIGNOR in, to, and deriving from the invention(s) disclosed in the patent application(s) set forth below may not have been transferred, for good and valuable consideration paid to ASSIGNOR by ASSIGNEE, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby assigns, sells and transfers to ASSIGNEE, and to ASSIGNEE'S successors and assigns, for the territory of the United States of America and its possessions all of ASSIGNOR'S right, including the right to claim priority, title and interest in, to, and deriving from the invention(s) described in the patent application(s) listed below, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, or other U.S. patent applications claiming the benefit of the filing date of the following patent application(s):

Case No.	Country	Filing Date	Serial No.
P37221-US	US	19, November, 2021	63/281133

entitled

NOVEL PYRIDINE COMPOUNDS

ASSIGNEE, by virtue of this Assignment, shall have the right to file and own patent applications that claim priority to and are based in whole or in part on the patent application(s) cited above with the United States Patent and Trademark Office and to own Letters Patents that issue thereon. Accordingly, ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks to issue any United States Letters Patent which may issue for such patent applications, including any divisions, renewals, continuations in whole or in part, substitutions, conversions, reissues, reexaminations, prolongations or extensions thereof, to ASSIGNEE, its successors and assigns.

ASSIGNOR does hereby covenant and agree with ASSIGNEE, its successors and assigns, that ASSIGNOR will not execute any writing or do any act conflicting with this assignment, and ASSIGNOR further agrees that he will, without charge to said ASSIGNEE, but at ASSIGNEE'S expense, cooperate with ASSIGNEE in the prosecution of said Letters Patent and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as ASSIGNEE lawfully may request, to obtain or maintain Letters Patent for said invention and improvement in any and all countries, and to vest title thereto in said ASSIGNEE, or ASSIGNEE'S successors and assigns.

Case No. P37221

This agreement shall be governed and construed in accordance with substantive laws of Switzerland, with the exclusion of the Vienna Convention on the International Sale of Goods dated April 11, 1980. The competent courts of Basel City, Switzerland shall have exclusive jurisdiction.

ASSIGNOR

F. Hoffmann – La Roche AG

Basel, Date

October 27, 2022, Natoli

Antonio Natoli
Holder of procuration

Petra Querfeld
Mandatory

ASSIGNEE

Hoffmann - La Roche Inc.

Newark, NJ - October 27, 2022
Place, Date

Samuel H. Megerditchian
Signatures Samuel H. Megerditchian
Authorized Signatory



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOVEMBER 14, 2022

PTAS

IP DOCKET ADMINISTRATOR
ONE GATEWAY CENTER
GIBBONS P.C.
NEWARK, NJ 07102

507594513

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 11/11/2022

REEL/FRAME: 061741/0457
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 036844-106335 (P37221)

ASSIGNOR:
ICAGEN, INC.

DOC DATE: 11/01/2022

ASSIGNEE:
ICAGEN, LLC
5980 HORTON STREET, SUITE 600
EMERYVILLE, CALIFORNIA 94608

APPLICATION NUMBER: 63281133
PATENT NUMBER:
TITLE: NOVEL PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

APPLICATION NUMBER: 63281140
PATENT NUMBER:
TITLE: PYRIDINE COMPOUNDS

FILING DATE: 11/19/2021
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

QUITCLAIM ASSIGNMENT

WHEREAS, **Icagen, Inc.**, a Delaware corporation, having an address at 8773 Lewis River Road, Delray Beach, FL, 33446 (hereinafter "ASSIGNOR") and Adjacent Acquisition Co., LLC, a Delaware limited liability company (hereinafter "Adjacent Acquisition"), entered into an Asset Purchase Agreement dated February 11, 2020 whereby Adjacent Acquisition acquired, among other things, all of then ASSIGNOR's right, title and interest in, to and under all intellectual property rights related to then ASSIGNOR's drug discovery business operated from then ASSIGNOR's Durham, North Carolina location (hereinafter "Assigned Intellectual Property");

WHEREAS, certain new and useful improvements described in the patent applications listed below (hereinafter "the Applications") constitute Assigned Intellectual Property (hereafter "Assigned Improvements");

<u>Application No.</u>	<u>Filing Date</u>	<u>Title</u>
63/281,133	November 19, 2021	NOVEL PYRIDINE COMPOUNDS
63/281,140	November 19, 2021	NOVEL PYRIDINE COMPOUNDS
63/292,482	December 22, 2021	NOVEL CYCLOPROPYL COMPOUNDS
63/310,219	February 15, 2022	NEW BICYCLOPENTANE DERIVATIVES;

WHEREAS, on April 2, 2020, Adjacent Acquisition changed its name to **Icagen, LLC**, having an address at 5980 Horton Street, Suite 600, Emeryville, CA 94608 (hereinafter "ASSIGNEE");

AND WHEREAS, ASSIGNEE desires to confirm that ASSIGNOR has assigned ASSIGNOR's rights in Assigned Improvements to ASSIGNEE.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR hereby acknowledges that ASSIGNOR has sold, assigned, transferred, and set over its entire right, title, and interest throughout the world in and to the Assigned Improvements, and by these presents does hereby sell, assign, transfer, and set over, unto said ASSIGNEE, its successors, legal representatives, and assigns, its entire right, title, and interest throughout the world in and to the Assigned Improvements in the Applications including:

the Assigned Improvements in all United States and foreign patents and utility models and applications therefor, and all reissues, divisionals, reexaminations, renewals, extensions, provisionals, supplementary protection certificates, continuations and continuations-in-part, and equivalent or similar registered rights anywhere in the World.


AND ASSIGNOR DOES HEREBY sell, assign, transfer, and convey to ASSIGNEE, its successors, legal representatives, and assigns all claims for damages and all remedies arising out of any violation of the rights assigned hereby that may have accrued prior to the date of assignment to ASSIGNEE, or may accrue hereafter, including, but not limited to, the right to sue for, collect, and retain damages for past infringements of Assigned Improvements in said Letters Patent before or after issuance.

ASSIGNOR retains its entire right, title, and interest throughout the world to any new and useful improvements owned by ASSIGNOR which do not constitute Assigned Improvements.

IN TESTIMONY WHEREOF, I hereunto set my hand and seal this ____ day of _____,
20____.

Icagen, Inc. (Conveying Party)

Icagen, LLC (Receiving Party)

By: 

By: 

Name: Richie Cunningham

Name: Douglas Krafte

Title: President & CEO

Title: Site Head and General Manager

Date: 11-1-2022

Date: NOV 3, 2022

Signature before a Notary is desirable but not required. When signed in presence of a Notary,
please attach the appropriate notarial documentation.

ASSIGN-ENTITY

56298847